Form D · Biotechnology
EnGeneIC Ltd
New South Wales, C3 · CIK 0001648902
Offering snapshot reported Apr 13, 2017 · SEC filing
- Reported sold
- $150K Offering amount: $10M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 4, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 13, 2017 | Initial | $150,000 | No comparison | 3 | SEC filing |
| Jul 29, 2015 | Initial | $2,905,000 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-284694
Source: Form D, filed Apr 13, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Himanshu Brahmbhatt | Director, Executive, Promoter |
| William Louis Delaat | Director |
| Jennifer Mac Diarmid | Director, Executive, Promoter |
| Edward Miller | Director |
| Yvonne Perlberg | Director |
| David Seaton | Executive |
| Mervyn Turner | Director |
| Stuart Wardman Browne | Director |
| Richard Woods | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
Building 2 25 Sirius Road, Lone Cove
New South Wales, C3, 2066
New South Wales, C3, 2066